<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="review-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">JIC</journal-id>
<journal-id journal-id-type="hwp">spjic</journal-id>
<journal-id journal-id-type="nlm-ta">J Intensive Care Med</journal-id>
<journal-title>Journal of Intensive Care Medicine</journal-title>
<issn pub-type="ppub">0885-0666</issn>
<issn pub-type="epub">1525-1489</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0885066610395489</article-id>
<article-id pub-id-type="publisher-id">10.1177_0885066610395489</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Analytic Reviews</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Etiology and Management of Hyponatremia in Neurosurgical Patients</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Upadhyay</surname>
<given-names>Urvashi M.</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-0885066610395489">1</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Gormley</surname>
<given-names>William B.</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-0885066610395489">1</xref>
<xref ref-type="corresp" rid="corresp1-0885066610395489"/>
</contrib>
</contrib-group>
<aff id="aff1-0885066610395489"><label>1</label>Department of Neurosugery, Brigham and Women’s Hospital, Harvard Medical School, 75 Francis Street, Boston, MA, USA</aff>
<author-notes>
<corresp id="corresp1-0885066610395489">William B. Gormley, Department of Neurosurgery, Brigham and Women’s Hospital/Harvard Medical School, 75 Francis Street, Carrie Hall 4, Boston, MA, USA Email: <email>wgormley@partners.org</email>
</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>5</month>
<year>2012</year>
</pub-date>
<volume>27</volume>
<issue>3</issue>
<fpage>139</fpage>
<lpage>144</lpage>
<history>
<date date-type="received">
<day>1</day>
<month>3</month>
<year>2010</year>
</date>
<date date-type="rev-recd">
<day>23</day>
<month>6</month>
<year>2010</year>
</date>
</history>
<permissions>
<copyright-statement>© The Author(s) 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>Hyponatremia is the most common electrolyte disorder encountered in neurosurgical patients. The aggressive treatment of hyponatremia in this group is critical, as hyponatremia can lead to mental status changes, seizures, vasospasm, cerebral edema, and even death. When it occurs, it represents a failure of one of several homeostatic mechanisms that tightly regulate serum sodium. In these patients, hyponatremia is most commonly due to the syndrome of inappropriate antidiuretic hormone (SIADH) or cerebral salt wasting (CSW). It can be problematic to differentiate between these 2 as they share key features, including low serum sodium, low serum osmolality, a higher urine osmolality than serum osmolality, and an elevated urinary sodium concentration. Furthermore, distinctions between CSW and SIADH, namely extracellular fluid (ECF) volume and total sodium balance, are often difficult to establish. Syndrome of inappropriate antidiuretic hormone is characterized by a volume-expanded state, whereas CSW is characterized by a volume-contracted state. Determining the exact cause remains a clinical imperative as the treatment for each is different. The rate at which serum sodium is corrected must be attended to, as rapid shifts in serum sodium pose potential risk of cerebral pontine myelinolysis.</p>
</abstract>
<kwd-group>
<kwd>hyponatremia</kwd>
<kwd>SIADH</kwd>
<kwd>cerebral salt wasting</kwd>
</kwd-group>
<custom-meta-wrap>
<custom-meta>
<meta-name>cover-date</meta-name>
<meta-value>May/June 2012</meta-value>
</custom-meta>
</custom-meta-wrap>
</article-meta>
</front>
<body>
<p>Hyponatremia is the most commonly encountered electrolyte disorder in the neurosurgical patient population. Severe hyponatremia can result in cerebral edema and symptoms of hyponatremia reflect its effect on the central nervous system. The severity of symptoms of hyponatremia are highly correlated with magnitude and its rapidity of onset. Early symptoms include headache, nausea, vomiting; as hyponatremia becomes more severe, patients develop confusion, seizures, stupor, and, eventually, coma.<sup><xref ref-type="bibr" rid="bibr1-0885066610395489">1</xref></sup>
</p>
<p>In the neurosurgical patient, hyponatremia is most commonly attributed to 1 of 2 conditions: the syndrome of inappropriate antidiuretic hormone (SIADH) or cerebral salt wasting (CSW).<sup><xref ref-type="bibr" rid="bibr1-0885066610395489">1</xref>,<xref ref-type="bibr" rid="bibr2-0885066610395489">2</xref></sup> Cerebral salt wasting is a condition characterized by hyponatremia, polyuria, and a dehydrated state. Syndrome of inappropriate antidiuretic hormone is a condition of hyponatremia resulting from inappropriate water retention. Both have been described in varied neurosurgical patient populations, including those with traumatic brain injury, aneurysmal subarachnoid hemorrhage (SAH), tumors in the region of the hypothalamic-pituitary axis, and occasionally in patients following surgery in this location.<sup><xref ref-type="bibr" rid="bibr3-0885066610395489">3</xref></sup> Central nervous system (CNS) tumors located in the hypothalamic-pituitary region tend to present with either of these conditions, whereas tumors outside this axis present predominantly with SIADH. Other causes such as meningeal carcinomatosis, meningitis, and ventriculitis are rare.<sup><xref ref-type="bibr" rid="bibr3-0885066610395489">3</xref></sup>
</p>
<p>The incidence of hyponatremia depends largely on the patient population being studied. In hospitalized patients on a general medical service, the incidence approaches 20%, while the condition only appears to afflict 3% of the ambulatory population.<sup><xref ref-type="bibr" rid="bibr4-0885066610395489">4</xref></sup> In neurosurgical patients, the incidence has been reported to be as high as 50%.<sup><xref ref-type="bibr" rid="bibr5-0885066610395489">5</xref></sup> Hyponatremic patients, especially those with severe hyponatremia (serum sodium less than 125mEq/L) experience an increase in mortality rates. In a study of medical patients (hospitalized for reasons other than hyponatremia) serum sodium levels less than 130 mmol/L were associated with a 60-fold increase in fatality (11.2% versus 0.19%).<sup><xref ref-type="bibr" rid="bibr5-0885066610395489">5</xref></sup> The mortality rate appears to correlate strongly with the level of hyponatremia; that is, patients with a serum sodium less than 120 mmol/L had a mortality rate of 25% compared with 9.3% in patients with normal sodium.<sup><xref ref-type="bibr" rid="bibr5-0885066610395489">5</xref></sup> Other studies have cited that the mortality rate approaches 50% in patients with serum sodium less than 120 mEq/L.<sup><xref ref-type="bibr" rid="bibr6-0885066610395489">6</xref></sup> Given the increased risk of mortality, hyponatremia in the critically-ill patient requires prompt and appropriate intervention. In hospitalized neurosurgical patients, these extreme levels of hyponatremia are rarely reached, as early aggressive interventions is the norm even in patients with moderate levels of hyponatremia (Na 126-135). Mild hyponatremia (Na 131-135) is rarely tolerated in this specialized patient population, as there is an increased focus on the effects of hyponatremia on cerebral edema in the setting of existing CNS pathology.</p>
<sec id="section1-0885066610395489">
<title>Homeostatic Mechanisms Regulating Serum Sodium</title>
<p>The normal concentration of sodium in the blood plasma is 136-145 mmol/L. Maintaining this range of serum sodium requires the synchronized work of several organ systems including the hypothalamus, adrenal gland, and kidney. Among the homeostatic mechanisms utilized are the induction of thirst, the release of antidiuretic hormone (ADH or vasopressin) and the regulation of the renal filtration of sodium.</p>
<p>Osmoreceptors in the hypothalamus sense extracellular sodium and water levels and respond in one of 2 ways to maintain normal sodium levels.<sup><xref ref-type="bibr" rid="bibr7-0885066610395489">7</xref></sup> In the case when sodium levels are too high, the hypothalamus stimulates the sensation of thirst. This is accomplished through the production of vasopressin by neurons in the hypothalamic supraoptic nuclei (SON) and paraventricular nuclei (PVN), themselves osmoreceptors. There is also synaptic input from other osmoreceptors in the organum vasculosum of the lamina terminalis and the subfornical organ.<sup><xref ref-type="bibr" rid="bibr7-0885066610395489">7</xref>,<xref ref-type="bibr" rid="bibr8-0885066610395489">8</xref></sup> Vasopressin, or ADH, has 2 main downstream effects on serum sodium levels. Mediated by vasopressin V2 receptor on the basolateral surface of principle cells in the kidney, ADH works at the distal renal tubule and collecting duct to cause differential retention of water but not solute, resulting in expansion of circulating plasma with solute dilution.<sup><xref ref-type="bibr" rid="bibr9-0885066610395489">9</xref></sup> Specifically, ADH increases the permeability to water by insertion of aquaporin water channels, which allow free water to be reabsorbed from the collecting duct within the hypertonic renal medulla. Secondly, vasopressin stimulates sodium and chloride reabsorption in the thick ascending limb of the loop of Henle by increasing the activity of the Na<sup>+</sup>-K<sup>+</sup>-2Cl<sup>-</sup>-co transporter. NaCl reabsorption then drives the osmotic gradient for aquaporin-mediated water reabsorption in the medullary collecting ducts.<sup><xref ref-type="bibr" rid="bibr8-0885066610395489">8</xref>,<xref ref-type="bibr" rid="bibr10-0885066610395489">10</xref></sup> Given the excessive water reabsorption as compared to sodium reabsorption, it becomes apparent how an inappropriate elevation of ADH can cause hyponatremia.</p>
<p>At the level of the adrenal gland, deficiencies in serum sodium, often reflected by increases in circulating potassium levels, stimulate the synthesis and release of the mineralocorticoid aldosterone from the zona glomerulosa in the adrenal cortex.<sup><xref ref-type="bibr" rid="bibr10-0885066610395489">10</xref></sup> Circulating aldosterone binds the nuclear mineralocorticoid receptors (MR) within the principal cells of the distal tubule and the collecting duct of the nephron.<sup><xref ref-type="bibr" rid="bibr10-0885066610395489">10</xref>,<xref ref-type="bibr" rid="bibr11-0885066610395489">11</xref></sup> Through this less potent mechanism, it increases the permeability of the apical (luminal) membrane to potassium and sodium and activates the basolateral Na+/K+ pumps, resulting in increased sodium reabsorption and potassium secretion.</p>
<p>Cerebral salt wasting and SIADH represent some disruption of these homeostatic mechanisms. While CSW is a well-described condition, its cause still remains unclear. There are 2 mechanisms that currently dominate the thought on its pathophysiology. The first suggests CSW is due to the disruption of cerebral sympathetic input to the kidney primarily affecting salt and water reabsorption in the proximal tubule and the release of renin.<sup><xref ref-type="bibr" rid="bibr12-0885066610395489">12</xref></sup> Diminished sympathetic signaling therefore results in a failure of appropriate proximal sodium reabsorption; further failure of renin and aldosterone release then results in the inability to respond to volume depletion. This theory is supported by the observation that in CSW, in the setting of increased distal tubule sodium levels, expected potassium wasting is not seen.</p>
<p>The second theory postulates that in patients with brain injury, a circulating factor is released that interferes with normal renal tubular sodium reabsorption. Brain natriuretic peptide (BNP) and atrial natriuretic peptide (ANP) have both been suggested as possible candidates as they are both known to decrease sodium reabsorption and inhibit renin release. Both hormones also affect autonomic output at the level of the brain stem.<sup><xref ref-type="bibr" rid="bibr13-0885066610395489">13</xref><xref ref-type="bibr" rid="bibr14-0885066610395489"/><xref ref-type="bibr" rid="bibr15-0885066610395489"/>–<xref ref-type="bibr" rid="bibr16-0885066610395489">16</xref></sup> It has been postulated that BNP is released in the settings of both increased intracranial pressure (ICP) and SAH. In a study measuring serum BNP levels in postcraniotomy brain tumor patients, patients with SAH, and age-matched controls, patients with SAH had a markedly elevated mean plasma BNP level (mean 15·1 [SE 3·8] vs. 1·6 [1·0] pmol/L, <italic>P</italic> &lt; .001), as well as increase in urine output and urine sodium concentration.<sup><xref ref-type="bibr" rid="bibr13-0885066610395489">13</xref></sup> Of note, these patients with SAH were noted to have normal plasma levels of ANP as compared to controls, suggesting that BNP is more likely the circulating factor of interest.<sup><xref ref-type="bibr" rid="bibr13-0885066610395489">13</xref></sup>
</p>
<p>In the neurosurgical patient population, SIADH is attributed to excess production of ADH in the hypothalamus and subsequent release into the posterior pituitary. As stated, under normal circumstances, ingestion of free water results in dilution of plasma. Osmoreceptors in the hypothalamus normally respond with a decrease in ADH release, however, in the case of SIADH, this feedback does not alter the release of ADH. The resulting enhanced reabsorption of water, leads to more concentrated urine, inability to excrete water, and consequently hyponatremia. In contrast to CSW, SIADH is a dysfunction in the handling of water, rather than solute.</p>
</sec>
<sec id="section2-0885066610395489">
<title>Differential Diagnosis</title>
<p>In the neurosurgical patient population, hyponatremia is attributed most often to SIADH or CSW. Differentiating which entity is responsible for the condition remains a challenge in the critical care management of these patients. While the treatment of these conditions may overlap in some cases, the principles guiding these treatments are quite different and in some cases, there is marked divergence in their treatments. Pursuing the incorrect course of treatment could have dangerous consequences for patients. For example, fluid restriction of a patient with CSW, misdoagnosed as SIADH, is never acceptable and would have dangerous consequences. This is particularly true in the case of CSW in the setting of SAH-induced vasospasm in which volume depletion can be catastrophic. The diagnostic approach to such patients requires history and physical examination, appropriate laboratory studies, and particular attention to the patient’s volume status.</p>
<sec id="section3-0885066610395489">
<title>Cerebral Salt Wasting</title>
<p>Cerebral salt wasting remains an important cause of hyponatremia in neurosurgical patients, particularly those presenting with SAH, though it has been described in other CNS conditions.<sup><xref ref-type="bibr" rid="bibr17-0885066610395489">17</xref></sup> In a retrospective review of over 300 patients with SAH and hyponatremia, 69% of patients were diagnosed with SIADH and 7% were diagnosed with CSW,<sup><xref ref-type="bibr" rid="bibr2-0885066610395489">2</xref></sup> other authors have reported incidence of CSW to be as high as 80% in patients with SAH.<sup><xref ref-type="bibr" rid="bibr12-0885066610395489">12</xref></sup> While it is most commonly seen in patients with SAH, it has also been described in patients with infectious meningitis, meningeal carcinomatosis, certain CNS tumors and following CNS injury and surgery.<sup><xref ref-type="bibr" rid="bibr17-0885066610395489">17</xref><xref ref-type="bibr" rid="bibr18-0885066610395489"/><xref ref-type="bibr" rid="bibr19-0885066610395489"/>–<xref ref-type="bibr" rid="bibr20-0885066610395489">20</xref></sup> Therefore, the diagnosis of CSW should be considered in any neurosurgical patient with hyponatremia. CSW-induced hyponatremia most often occurs within 10 days after a neurosurgical procedure or event, even though there are case reports suggesting it may appear as late as 1 month after such events.<sup><xref ref-type="bibr" rid="bibr12-0885066610395489">12</xref>,<xref ref-type="bibr" rid="bibr17-0885066610395489">17</xref></sup>
</p>
<p>As mentioned, 2 mechanisms have been suggested for the pathophysiology of CSW. Whichever mechanism is responsible for CSW, the response may be the perversion of an otherwise protective mechanism. That is, renal salt wasting and the resulting volume depletion may limit rises in intracranial pressure. Further, BNP has been shown to have vasodilatory properties that may counteract the tendency for vasospasm in patients with SAH.<sup><xref ref-type="bibr" rid="bibr21-0885066610395489">21</xref>,<xref ref-type="bibr" rid="bibr22-0885066610395489">22</xref></sup> This postulate appears possible as it has been shown that BNP has vasodilatory properties on coronary vessels.<sup><xref ref-type="bibr" rid="bibr22-0885066610395489">22</xref></sup> Regardless, it is clear that the dehydration associated with CSW is detrimental for patients with SAH in vasospam. While the majority of neurosurgeons recognize CSW as a common cause of hyponatremia in neurosurgical patients, it should be mentioned that a few authors have argued that CSW is not a real entity; instead they propose that patients with elevated sodium excretion may be responding normally to the volume expansion (due to intravenous fluid administration for the prevention of vasospasm in patients with SAH).<sup><xref ref-type="bibr" rid="bibr23-0885066610395489">23</xref></sup> However, elevated sodium excretion has not been observed in patients undergoing volume expansion with isotonic saline in the setting of various other clinical indications. Most neurosurgeons and neuro-intensivists accept CSW as a real clinical entity.</p>
<p>Diagnosis of CSW relies largely on differentiating it from SIADH. This may prove difficult as both diagnoses share many laboratory features, other than hyponatremia. In the setting of hypovolemia, regardless of the cause, ADH release increases, resulting in high urine osmolality. Unlike in SIADH, this reaction is appropriate in the case of CSW, given its inherent volume depletion. Urine sodium is also elevated in both conditions. The only unique characteristic of CSW is that patients are in a state of relative hypovolemia. Patients may exhibit consequences of this hypovolemia such as hypotension, elevated hematocit, or poor skin turgor.</p>
</sec>
<sec id="section4-0885066610395489">
<title>Syndrome of Inappropriate Antidiuretic Hormone</title>
<p>Syndrome of inappropriate antidiuretic hormone is a condition characterized by excessive antidiuretic hormone-induced water retention and resultant hyponatremia. Plasma volume expansion follows, thereby activating secondary natriuretic mechanisms, resulting in sodium and water loss. In later stages, a state of near euvolemia is reached since the net loss of sodium is far more prominent than water retention.<sup><xref ref-type="bibr" rid="bibr24-0885066610395489">24</xref>,<xref ref-type="bibr" rid="bibr25-0885066610395489">25</xref></sup> In fact, it is this state of euvolemia that distinguishes SIADH from CSW.<sup><xref ref-type="bibr" rid="bibr26-0885066610395489">26</xref></sup> The causes of SIADH are widespread from the neoplastic (lung or brain tumors), infectious (meningitis, brain abscesses), to traumatic brain injury.</p>
<p>Diagnosis of SIADH is made by hyponatremia, serum hypoosmolality, inappropriately elevated urine osmolality, low blood urea nitrogen (BUN) and serum uric acid concentration, and in later stages, clinical euvolemia. Distinguishing SIADH from CSW can be challenging as its only unique feature may be a normal volume status. Among these patients, it is essential to eliminate thyroid or adrenal abnormalities.</p>
</sec>
</sec>
<sec id="section5-0885066610395489">
<title>Treatment</title>
<sec id="section6-0885066610395489">
<title>Identifying the Underlying Cause</title>
<p>The treatment of hyponatremia depends entirely on identifying the underlying cause of the disorder (<xref ref-type="table" rid="table1-0885066610395489">Table 1</xref>
). Treatment of CSW is centered on restoration of euvolemia with isotonic saline administration and in more severe cases administration of hypertonic saline. In contrast, the patient with SIADH is treated most effectively with fluid restriction. Distinguishing the patient with hypovolemic hyponatremia (CSW) from the patient with euvolemic hyponatremia (SIADH) requires knowledge of patient’s volume status (<xref ref-type="table" rid="table1-0885066610395489">Table 1</xref>). In the case of patients with CSW, urine concentration of Na is generally in excess of 20 mEq/L, total fluid balance is negative and central venous pressures (CVP) are generally &lt;6 cm H<sub>2</sub>O.<sup><xref ref-type="bibr" rid="bibr27-0885066610395489">27</xref></sup> In some cases, evaluation of serum potassium, albumin, and hematocrit may shed additional light on the diagnosis of CSW or SIADH.<sup><xref ref-type="bibr" rid="bibr5-0885066610395489">5</xref>,<xref ref-type="bibr" rid="bibr28-0885066610395489">28</xref>,<xref ref-type="bibr" rid="bibr29-0885066610395489">29</xref></sup> However, often these parameters may be normal in patients, leaving volume status as the only reliable differentiator.</p>
<table-wrap id="table1-0885066610395489" position="float">
<label>Table 1.</label>
<caption>
<p>Comparison of Laboratory and Clinical Parameters in SIADH vs CSW10,24,3
0
</p>
</caption>
<graphic alternate-form-of="table1-0885066610395489" xlink:href="10.1177_0885066610395489-table1.tif"/>
<table>
<thead>
<tr>
<th>Parameter</th>
<th>CSW</th>
<th>SIADH</th>
</tr>
</thead>
<tbody>
<tr>
<td>24-hour fluid balance</td>
<td>Negative</td>
<td>Even or slightly positive</td>
</tr>
<tr>
<td>CVP</td>
<td>&lt;6 cm H<sub>2</sub>O</td>
<td>&gt; 6 cm H<sub>2</sub>O</td>
</tr>
<tr>
<td>Urine sodium excretion</td>
<td>&gt; 20 mEq/L</td>
<td>&gt;20 mEq/L</td>
</tr>
<tr>
<td>Serum albumin</td>
<td>Increased</td>
<td>Normal</td>
</tr>
<tr>
<td>Hematocrit</td>
<td>Increased</td>
<td>Normal</td>
</tr>
<tr>
<td>Serum potassium</td>
<td>Increased or no change</td>
<td>Decreased or no change</td>
</tr>
<tr>
<td>Jugular venous distention</td>
<td>Absent</td>
<td>Present</td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
<sec id="section7-0885066610395489">
<title>Rate of Correction</title>
<p>The rate of serum sodium correction depends largely on the chronicity of the hyponatremia. In the case of acute hyponatremia, the therapeutic goal is to increase the serum sodium level rapidly by 4 to 6 mEq/L over the first 1 to 2 hours.<sup><xref ref-type="bibr" rid="bibr5-0885066610395489">5</xref></sup> The addition of hypertonic saline (in the form of 3% saline or 23.4% saline in more extreme cases) should be used in the cases where the hyponatremia is acute, severe (eg, Na &lt;125), and patients are displaying neurologic changes. The uppermost concerns for these patients is the development of brainstem compression from rapidly expanding cerebral edema and secondary herniation.<sup><xref ref-type="bibr" rid="bibr27-0885066610395489">27</xref></sup> The need to correct sodium levels quickly is tempered by the real threat of development of central pontine myelinolysis if correction is too rapid, particularly in the setting of chronic hyponatremia. Central pontine myelinolysis (CPM) is a neurologic state caused by severe damage to the myelin sheath of pontine fibers most commonly caused by rapid correction of hyponatremia.<sup><xref ref-type="bibr" rid="bibr29-0885066610395489">29</xref></sup> The severe form of the condition is characterized by irreversible quadraparesis, dysarthria, and loss of consciousness. The risk of osmotic demyelination that causes CPM is minimized in patients with chronic hyponatremia when the serum sodium is corrected at a rate not to exceed 10 to 12 mEq/L in the first 24 hours and not to exceed 18 mEq/L in the first 2 days.<sup><xref ref-type="bibr" rid="bibr28-0885066610395489">28</xref>,<xref ref-type="bibr" rid="bibr29-0885066610395489">29</xref></sup>
</p>
<p>In contrast to CSW where treatment is focused on sodium and volume replacement, the treatment in SIADH is focused on increasing sodium intake with control of free water intake, where patients are placed on fluid restriction. Confidence in the diagnosis of SIADH is paramount here, as fluid restriction of the patient with CSW can have disastrous consequences. This is particularly true in the aneurysmal SAH patient at risk for vasospasm and cerebral ischemia. As is the case with CSW, addition of hypertonic saline is necessary when patients develop neurologic symptoms or the hyponatremia is acute in onset. In the neurosurgical patient, decreases in serum sodium are not tolerable given the real risk of increased cerebral edema. Given that, the threshold for addition of hypertonic saline is lower for the neurosurgical patient population as compared with medical populations without intracranial pathology. It may be necessary in these patients to calculate total body sodium deficit as suggested by Androgue et al.<sup><xref ref-type="bibr" rid="bibr29-0885066610395489">29</xref></sup>
</p>
<p>
<disp-formula id="disp-formula1-0885066610395489">
<mml:math id="mml-disp1-0885066610395489">
<mml:mtable columnalign="right left" columnspacing="thickmathspace" displaystyle="true" rowspacing=".5em">
<mml:mtr>
<mml:mtd>
<mml:mrow>
<mml:mi mathvariant="normal">S</mml:mi>
<mml:mi mathvariant="normal">o</mml:mi>
<mml:mi mathvariant="normal">d</mml:mi>
<mml:mi mathvariant="normal">i</mml:mi>
<mml:mi mathvariant="normal">u</mml:mi>
<mml:mi mathvariant="normal">m</mml:mi>
<mml:mtext mathvariant="normal"> </mml:mtext>
<mml:mi mathvariant="normal">d</mml:mi>
<mml:mi mathvariant="normal">e</mml:mi>
<mml:mi mathvariant="normal">f</mml:mi>
<mml:mi mathvariant="normal">i</mml:mi>
<mml:mi mathvariant="normal">c</mml:mi>
<mml:mi mathvariant="normal">i</mml:mi>
<mml:mi mathvariant="normal">t</mml:mi>
<mml:mtext mathvariant="normal"> </mml:mtext>
<mml:mo mathvariant="normal" stretchy="false">(</mml:mo>
<mml:mi mathvariant="normal">m</mml:mi>
<mml:mi mathvariant="normal">a</mml:mi>
<mml:mi mathvariant="normal">l</mml:mi>
<mml:mi mathvariant="normal">e</mml:mi>
<mml:mo mathvariant="normal" stretchy="false">)</mml:mo>
</mml:mrow>
<mml:mo mathvariant="normal" stretchy="false">=</mml:mo>
<mml:mn mathvariant="normal">0.6</mml:mn>
<mml:mo stretchy="false">×</mml:mo>
<mml:mo mathvariant="normal" stretchy="false">(</mml:mo>
<mml:mrow>
<mml:mi mathvariant="normal">b</mml:mi>
<mml:mi mathvariant="normal">o</mml:mi>
<mml:mi mathvariant="normal">d</mml:mi>
<mml:mi mathvariant="normal">y</mml:mi>
<mml:mtext mathvariant="normal"> </mml:mtext>
<mml:mi mathvariant="normal">w</mml:mi>
<mml:mi mathvariant="normal">e</mml:mi>
<mml:mi mathvariant="normal">i</mml:mi>
<mml:mi mathvariant="normal">g</mml:mi>
<mml:mi mathvariant="normal">h</mml:mi>
<mml:mi mathvariant="normal">t</mml:mi>
<mml:mtext mathvariant="normal"> </mml:mtext>
<mml:mi mathvariant="normal">i</mml:mi>
<mml:mi mathvariant="normal">n</mml:mi>
<mml:mtext mathvariant="normal"> </mml:mtext>
<mml:mi mathvariant="normal">m</mml:mi>
<mml:mi mathvariant="normal">g</mml:mi>
</mml:mrow>
<mml:mo mathvariant="normal" stretchy="false">)</mml:mo>
</mml:mtd>
</mml:mtr>
<mml:mtr>
<mml:mtd>
<mml:mrow>
<mml:mspace width="1em"/>
</mml:mrow>
<mml:mo stretchy="false">×</mml:mo>
<mml:mrow>
<mml:mi mathvariant="normal">d</mml:mi>
<mml:mi mathvariant="normal">e</mml:mi>
<mml:mi mathvariant="normal">s</mml:mi>
<mml:mi mathvariant="normal">i</mml:mi>
<mml:mi mathvariant="normal">r</mml:mi>
<mml:mi mathvariant="normal">e</mml:mi>
<mml:mi mathvariant="normal">d</mml:mi>
<mml:mtext mathvariant="normal"> </mml:mtext>
<mml:mi mathvariant="normal">s</mml:mi>
<mml:mi mathvariant="normal">o</mml:mi>
<mml:mi mathvariant="normal">d</mml:mi>
<mml:mi mathvariant="normal">i</mml:mi>
<mml:mi mathvariant="normal">u</mml:mi>
<mml:mi mathvariant="normal">m</mml:mi>
<mml:mtext mathvariant="normal"> </mml:mtext>
<mml:mo mathvariant="normal" stretchy="false">−</mml:mo>
<mml:mi mathvariant="normal">a</mml:mi>
<mml:mi mathvariant="normal">c</mml:mi>
<mml:mi mathvariant="normal">t</mml:mi>
<mml:mi mathvariant="normal">u</mml:mi>
<mml:mi mathvariant="normal">a</mml:mi>
<mml:mi mathvariant="normal">l</mml:mi>
<mml:mtext mathvariant="normal"> </mml:mtext>
<mml:mi mathvariant="normal">s</mml:mi>
<mml:mi mathvariant="normal">o</mml:mi>
<mml:mi mathvariant="normal">d</mml:mi>
<mml:mi mathvariant="normal">i</mml:mi>
<mml:mi mathvariant="normal">u</mml:mi>
<mml:mi mathvariant="normal">m</mml:mi>
<mml:mo mathvariant="normal" stretchy="false">)</mml:mo>
<mml:mo mathvariant="normal">.</mml:mo>
</mml:mrow>
</mml:mtd>
</mml:mtr>
<mml:mtr>
<mml:mtd>
<mml:mrow>
<mml:mi mathvariant="normal">S</mml:mi>
<mml:mi mathvariant="normal">o</mml:mi>
<mml:mi mathvariant="normal">d</mml:mi>
<mml:mi mathvariant="normal">i</mml:mi>
<mml:mi mathvariant="normal">u</mml:mi>
<mml:mi mathvariant="normal">m</mml:mi>
<mml:mtext mathvariant="normal"> </mml:mtext>
<mml:mi mathvariant="normal">d</mml:mi>
<mml:mi mathvariant="normal">e</mml:mi>
<mml:mi mathvariant="normal">f</mml:mi>
<mml:mi mathvariant="normal">i</mml:mi>
<mml:mi mathvariant="normal">c</mml:mi>
<mml:mi mathvariant="normal">i</mml:mi>
<mml:mi mathvariant="normal">t</mml:mi>
<mml:mtext mathvariant="normal"> </mml:mtext>
<mml:mo mathvariant="normal" stretchy="false">(</mml:mo>
<mml:mi mathvariant="normal">f</mml:mi>
<mml:mi mathvariant="normal">e</mml:mi>
<mml:mi mathvariant="normal">m</mml:mi>
<mml:mi mathvariant="normal">a</mml:mi>
<mml:mi mathvariant="normal">l</mml:mi>
<mml:mi mathvariant="normal">e</mml:mi>
<mml:mo mathvariant="normal" stretchy="false">)</mml:mo>
</mml:mrow>
<mml:mo mathvariant="normal" stretchy="false">=</mml:mo>
<mml:mn mathvariant="normal">0.5</mml:mn>
<mml:mo stretchy="false">×</mml:mo>
<mml:mo mathvariant="normal" stretchy="false">(</mml:mo>
<mml:mrow>
<mml:mi mathvariant="normal">b</mml:mi>
<mml:mi mathvariant="normal">o</mml:mi>
<mml:mi mathvariant="normal">d</mml:mi>
<mml:mi mathvariant="normal">y</mml:mi>
<mml:mtext mathvariant="normal"> </mml:mtext>
<mml:mi mathvariant="normal">w</mml:mi>
<mml:mi mathvariant="normal">e</mml:mi>
<mml:mi mathvariant="normal">i</mml:mi>
<mml:mi mathvariant="normal">g</mml:mi>
<mml:mi mathvariant="normal">h</mml:mi>
<mml:mi mathvariant="normal">t</mml:mi>
<mml:mtext mathvariant="normal"> </mml:mtext>
<mml:mi mathvariant="normal">i</mml:mi>
<mml:mi mathvariant="normal">n</mml:mi>
<mml:mtext mathvariant="normal"> </mml:mtext>
<mml:mi mathvariant="normal">m</mml:mi>
<mml:mi mathvariant="normal">g</mml:mi>
</mml:mrow>
<mml:mo mathvariant="normal" stretchy="false">)</mml:mo>
</mml:mtd>
</mml:mtr>
<mml:mtr>
<mml:mtd>
<mml:mrow>
<mml:mspace width="1em"/>
</mml:mrow>
<mml:mo stretchy="false">×</mml:mo>
<mml:mrow>
<mml:mi mathvariant="normal">d</mml:mi>
<mml:mi mathvariant="normal">e</mml:mi>
<mml:mi mathvariant="normal">s</mml:mi>
<mml:mi mathvariant="normal">i</mml:mi>
<mml:mi mathvariant="normal">r</mml:mi>
<mml:mi mathvariant="normal">e</mml:mi>
<mml:mi mathvariant="normal">d</mml:mi>
<mml:mtext mathvariant="normal"> </mml:mtext>
<mml:mi mathvariant="normal">s</mml:mi>
<mml:mi mathvariant="normal">o</mml:mi>
<mml:mi mathvariant="normal">d</mml:mi>
<mml:mi mathvariant="normal">i</mml:mi>
<mml:mi mathvariant="normal">u</mml:mi>
<mml:mi mathvariant="normal">m</mml:mi>
<mml:mtext mathvariant="normal"> </mml:mtext>
<mml:mo mathvariant="normal" stretchy="false">−</mml:mo>
<mml:mi mathvariant="normal">a</mml:mi>
<mml:mi mathvariant="normal">c</mml:mi>
<mml:mi mathvariant="normal">t</mml:mi>
<mml:mi mathvariant="normal">u</mml:mi>
<mml:mi mathvariant="normal">a</mml:mi>
<mml:mi mathvariant="normal">l</mml:mi>
<mml:mtext mathvariant="normal"> </mml:mtext>
<mml:mi mathvariant="normal">s</mml:mi>
<mml:mi mathvariant="normal">o</mml:mi>
<mml:mi mathvariant="normal">d</mml:mi>
<mml:mi mathvariant="normal">i</mml:mi>
<mml:mi mathvariant="normal">u</mml:mi>
<mml:mi mathvariant="normal">m</mml:mi>
<mml:mo mathvariant="normal" stretchy="false">)</mml:mo>
<mml:mo mathvariant="normal">.</mml:mo>
</mml:mrow>
</mml:mtd>
</mml:mtr>
</mml:mtable>
</mml:math>
<graphic alternate-form-of="disp-formula1-0885066610395489" xlink:href="10.1177_0885066610395489-eq1.tif"/>
</disp-formula>Using the above equations, the clinician can gain a sense of the severity of hyponatremia and the rapidity with which it may need correction. Success using such a strategy has been reported by Kurokawa et al who found very few neurological deficits related to ischemia following SAH while sodium levels were being thus corrected.<sup><xref ref-type="bibr" rid="bibr30-0885066610395489">30</xref></sup> In cases of severe, but chronic hyponatremia, slower correction may be appropriate. However, in the case of the neurosurgical patient with acute onset of severe hyponatremia, rapid and aggressive correction is necessary.</p>
</sec>
<sec id="section8-0885066610395489">
<title>Pharmacologic Intervention</title>
<p>In many cases, particularly in CSW, administration of supplemental sodium either orally or intravenously with isotonic or hypertonic sodium solutions may not be sufficient. In such cases, patients may benefit from pharmacologic adjuvants such as fludrocortisone acetate, a synthetic adrenocortical steroid with potent mineralocorticoid properties. It acts at the renal distal tubule to increase sodium reabsorption and may be used to counteract the natriuresis that occurs in CSW. The treatment of CSW remains an off-label indication for fludrocortisone, however, several groups have reported clinical improvement in hyponatremia, particularly in patients with SAH.<sup><xref ref-type="bibr" rid="bibr30-0885066610395489">30</xref>,<xref ref-type="bibr" rid="bibr31-0885066610395489">31</xref></sup> To date, no large-scale trial has examined its efficacy or safety, and therefore, it remains without strong data to support its use. In our institution, we have found it to be an important tool in the management of hyponatremia associated with patients having CSW.</p>
<p>Likewise, in the case of euvolemic hyponatremia, recently developed vasopressin receptor antagonists have shown some efficacy in treatment of SIADH.<sup><xref ref-type="bibr" rid="bibr32-0885066610395489">32</xref><xref ref-type="bibr" rid="bibr33-0885066610395489"/>–<xref ref-type="bibr" rid="bibr34-0885066610395489">34</xref></sup> Conivaptan is the first ADH receptor antagonist FDA approved for the treatment of euvolemic hyponatremia (SIADH). It must be emphasized that before the administration of any of the vasopressin receptor antagonists, the clinician must be sure that SIADH is the true cause of hyponatremia. Administration of conivaptan to a patient with CSW would significantly worsen the volume-depleted status of such patients. In a retrospective analysis of 22 patients with hyponatremia in the neurocritical care unit, treated with conivaptan, over 80% of patients achieved an increase in serum sodium of ≥6 mEq/L within 13 hours of administration.<sup><xref ref-type="bibr" rid="bibr32-0885066610395489">32</xref></sup> Infusion-site reactions were reported in a small percentage of patients and the authors report that the treatment was tolerated over a 4-day period. A randomized-controlled trial of Conivaptan in the treatment of 84 patients with euvolemic or hypervolemic hyponatremia reported similar success.<sup><xref ref-type="bibr" rid="bibr32-0885066610395489">32</xref></sup> Increases in sodium appeared to be dose-related; following a fixed loading dose, with an infusion rate of 40 mg/day, patients were noted to have an increase in serum sodium of 6.3 ± 0.7 mEq/L and with an infusion rate of 80 mg/day, patients demonstrated an increase of 9.4 ± 0.8 mEq/L.<sup><xref ref-type="bibr" rid="bibr32-0885066610395489">32</xref>,<xref ref-type="bibr" rid="bibr33-0885066610395489">33</xref></sup> Of note, the administration of conivaptan was associated with more significant adverse events including hypotension and hyperkalemia. The issue of whether permanent correction of hyponatremia is maintained after discontinuation of the drug must still be resolved. This is particularly important in SIADH, which has a tendency toward recurrence.</p>
</sec>
<sec id="section9-0885066610395489">
<title>Treatment Algorithm</title>
<p>In our Neurosurgical Critical Care unit, we have developed a treatment paradigm for patients presenting with hyponatremia. The goal of this approach is to limit delayed or inadequate interventions that are known to increase patient mortality in general and that of neurosurgical patients in particular (<xref ref-type="fig" rid="fig1-0885066610395489">Figure 1</xref>
).</p>
<fig id="fig1-0885066610395489" position="float">
<label>Figure 1.</label>
<caption>
<p>A proposed approach in the treatment of neurosurgical patients with hyponatremia.</p>
</caption>
<graphic alternate-form-of="fig1-0885066610395489" xlink:href="10.1177_0885066610395489-fig1.tif"/>
</fig>
</sec>
<sec id="section10-0885066610395489">
<title>Future Directions</title>
<p>While treatments for hyponatremia in neurosurgical patients are fairly successful at reinstating normal sodium levels, there remains much room for improvement both in diagnosis and treatment of the varied causes of hyponatremia. Specifically, there remains a need for elucidating the exact mechanism underlying CSW. Whether it is due to the central release of a circulating factor or to a disruption of normal autonomic input to the kidney, uncovering the precise cause will enable rational design of therapeutics that may prove more etiology-driven than volume expansion and salt repletion. Another area of interest is investigation of the clinical efficacy of vasopressin receptors antagonists currently available. While the preliminary data on conivaptan appears promising, it remains unclear how it should be used in combination with fluid restriction and whether cost and development of adverse events will limit its clinical utility in neurocritical care.</p>
</sec>
</sec>
<sec id="section11-0885066610395489">
<title>Conclusion</title>
<p>Hyponatremia in the neurosurgical critical care patient represents a failure of existing homeostatic mechanisms that maintain normonatremia. In contradistinction from medical critical care patients, the hyponatremic neurosurgical patient requires urgent intervention as the risks of increased cerebral edema are intolerable in patients with preexisting intracranial pathology. While there are numerous underlying causes, neurosurgical patients with hyponatremia are most likely afflicted with either CSW or SIADH. Differentiating these 2 conditions remains a clinical challenge; however, attention to the patient’s volume status is essential. A spectrum of therapeutic interventions is currently used, from management of fluid status to administration of hormonal agonists. Patient-specific goals of care are necessary and must be adopted swiftly to prevent the neurologic sequelae that may accompany low serum sodium.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="conflict" id="fn1-0885066610395489">
<p>The author(s) declared no conflicts of interest with respect to the authorship and/or publication of this article.</p>
</fn>
<fn fn-type="financial-disclosure" id="fn2-0885066610395489">
<p>The author(s) received no financial support for the research and/or authorship of this article.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-0885066610395489">
<label>1</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Rose</surname>
<given-names>BD</given-names>
</name>
<name>
<surname>Post</surname>
<given-names>TW.</given-names>
</name>
</person-group> <source>Clinical Physiology of Acid-Base and Electrolyte Disorders</source>.<edition>5th ed</edition>.
<year>2001</year>;<publisher-loc>New York</publisher-loc>: <publisher-name>McGraw-Hill</publisher-name>, <fpage>729</fpage>–<lpage>733</lpage>.</citation>
</ref>
<ref id="bibr2-0885066610395489">
<label>2</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sherlock</surname>
<given-names>M</given-names>
</name>
<name>
<surname>O’Sullivan</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Adha</surname>
<given-names>A</given-names>
</name>
<etal/>
</person-group>. <article-title>The incidence and pathophysiology of hyponatremia after subarachnoid hemorrhage</article-title>. <source>Crit Care Med</source>. <year>2006</year>;<volume>34</volume>(<issue>3</issue>):<fpage>617</fpage>.</citation>
</ref>
<ref id="bibr3-0885066610395489">
<label>3</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bartter</surname>
<given-names>FC</given-names>
</name>
<name>
<surname>Schwartz</surname>
<given-names>WB.</given-names>
</name>
</person-group> <article-title>“The syndrome of inappropriate secretion of antidiuretic hormone”</article-title>. <source>Am J Med</source>. <year>1967</year>;<volume>42</volume>(<issue>5</issue>):<fpage>790</fpage>–<lpage>806</lpage>.</citation>
</ref>
<ref id="bibr4-0885066610395489">
<label>4</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Simon</surname>
<given-names>EE</given-names>
</name>
<name>
<surname>Hamrahnian</surname>
<given-names>SM.</given-names>
</name>
</person-group>
<comment>Hyponatremia. Emedicine. Acid-Base Fluid Electrolyte Disorders. 5 2009</comment>
</citation>
</ref>
<ref id="bibr5-0885066610395489">
<label>5</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rahman</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Freidman</surname>
<given-names>WA.</given-names>
</name>
</person-group> <article-title>Hyponatremia in neurosurgical patients: clinical guidelines development</article-title>. <source>Neurosurgery</source>. <year>2009</year>;<volume>65</volume>(<issue>5</issue>):<fpage>925</fpage>–<lpage>936</lpage>.</citation>
</ref>
<ref id="bibr6-0885066610395489">
<label>6</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Dubois</surname>
<given-names>GD</given-names>
</name>
<name>
<surname>Arieff</surname>
<given-names>AI</given-names>
</name>
</person-group>
<article-title>Treatment of hyponatremia: the case for rapid correction</article-title>. In: <person-group person-group-type="editor">
<name>
<surname>Narins</surname>
<given-names>RG</given-names>
</name>
</person-group> (Ed.), <source>Controversies in Nephrology and Hypertension</source>.<year>1984</year>;<publisher-loc>New York</publisher-loc>: <publisher-name>Churchill Livingstone Inc</publisher-name>, <fpage>393</fpage>–<lpage>407</lpage>.</citation>
</ref>
<ref id="bibr7-0885066610395489">
<label>7</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tomohiro</surname>
<given-names>Osanai</given-names>
</name>
<name>
<surname>Naoto</surname>
<given-names>Fujiwara</given-names>
</name>
<name>
<surname>Masayuki</surname>
<given-names>Saitoh</given-names>
</name>
<etal/>
</person-group>. <article-title>Relationship between salt intake, nitric oxide and asymmetric dimethylarginine and its relevance to patients with end-stage renal disease</article-title>. <source>Blood Purif</source>. <year>2002</year>;<volume>20</volume>(<issue>5</issue>):<fpage>466</fpage>–<lpage>468</lpage>.</citation>
</ref>
<ref id="bibr8-0885066610395489">
<label>8</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Walter F</surname>
<given-names>Boron.</given-names>
</name>
</person-group> <source>Medical Physiology: A Cellular and Molecular Approach</source>. <comment>Elsevier/Saunders. ISBN1-4160-2328-3.2005:840</comment>
</citation>
</ref>
<ref id="bibr9-0885066610395489">
<label>9</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schwarts</surname>
<given-names>WB</given-names>
</name>
<name>
<surname>Bennett</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Curelop</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Bartter</surname>
<given-names>FC.</given-names>
</name>
</person-group> <article-title>A syndrome of renal sodium loss and hyponatremia probably resulting from inappropriate secretion of antidiuretic hormone</article-title>. <source>Am J Med</source>. <year>1957</year>;<volume>23</volume>(<issue>4</issue>):<fpage>529</fpage>–<lpage>542</lpage>.</citation>
</ref>
<ref id="bibr10-0885066610395489">
<label>10</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Rector Floyd</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Brenner Barry</surname>
<given-names>M.</given-names>
</name>
</person-group> <source>Brenner &amp; Rector’s the kidney</source>.<year>2004</year>;<publisher-loc>Philadelphia</publisher-loc>: <publisher-name>Saunders</publisher-name>, </citation>
</ref>
<ref id="bibr11-0885066610395489">
<label>11</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schneider</surname>
<given-names>EG</given-names>
</name>
<name>
<surname>Radke</surname>
<given-names>KJ</given-names>
</name>
<name>
<surname>Ulderich</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Taylor</surname>
<given-names>RE.</given-names>
</name>
</person-group> <article-title>Effect of osmolality on aldosterone secretion</article-title>. <source>Endocrinology</source>. <year>1985</year>;<volume>116</volume>(<issue>4</issue>):<fpage>1621</fpage>.</citation>
</ref>
<ref id="bibr12-0885066610395489">
<label>12</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Palmer</surname>
<given-names>BF.</given-names>
</name>
</person-group> <article-title>Hyponatremia in patients with central nervous system disease: SIADH vs. CSW</article-title>. <source>Trends Endocrinol Metab</source>. <year>2003</year>;<volume>14</volume>(<issue>4</issue>):<fpage>182</fpage>.</citation>
</ref>
<ref id="bibr13-0885066610395489">
<label>13</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Berendes</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Walter</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Cullen</surname>
<given-names>P</given-names>
</name>
<etal/>
</person-group>. <article-title>Secretion of brain natriuretic peptide in patients with aneurismal subarachnoid hemorrhage</article-title>. <source>Lancet</source>. <year>1997</year>;<volume>349</volume>(<issue>1</issue>):<fpage>245</fpage>.</citation>
</ref>
<ref id="bibr14-0885066610395489">
<label>14</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Berger</surname>
<given-names>TM</given-names>
</name>
<name>
<surname>Kistler</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Berendes</surname>
<given-names>E</given-names>
</name>
<etal/>
</person-group>. <article-title>Hyponatremia in a pediatric stroke patient: syndrome of inappropriate antidiuretic hormone or cerebral salt wasting?</article-title> <source>Crit Care Med</source>. <year>2002</year>;<volume>30</volume>(<issue>4</issue>):<fpage>792</fpage>.</citation>
</ref>
<ref id="bibr15-0885066610395489">
<label>15</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Harrigan</surname>
<given-names>MR.</given-names>
</name>
</person-group> <article-title>Cerebral salt wasting syndrome: a review</article-title>. <source>Neurosurgery</source>. <year>1996</year>;<volume>38</volume>(<issue>1</issue>):<fpage>152</fpage>.</citation>
</ref>
<ref id="bibr16-0885066610395489">
<label>16</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Singh</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Bohn</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Carlotti</surname>
<given-names>AP.</given-names>
</name>
</person-group> <article-title>Cerebral salt wasting: Truths, fallacies, theories, and challenges</article-title>. <source>Crit Care Med</source>. <year>2002</year>;<volume>30</volume>(<issue>11</issue>):<fpage>2575</fpage>.</citation>
</ref>
<ref id="bibr17-0885066610395489">
<label>17</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fillipella</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Cappabianca</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Cavallo</surname>
<given-names>LM</given-names>
</name>
<etal/>
</person-group>. <article-title>Very delayed hyponatremia after surgery and radiotherapy for pituitary macroadenoma</article-title>. <source>J Endocrinol Invest</source>. <year>2002</year>;<volume>25</volume>(<issue>2</issue>):<fpage>163</fpage>.</citation>
</ref>
<ref id="bibr18-0885066610395489">
<label>18</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sengupta</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Ali</surname>
<given-names>U</given-names>
</name>
<name>
<surname>Andankar</surname>
<given-names>P.</given-names>
</name>
</person-group> <article-title>Cerebral Salt Wasting</article-title>. <source>Indian Pediatr</source>. <year>2002</year>;<volume>39</volume>(<issue>5</issue>):<fpage>488</fpage>.</citation>
</ref>
<ref id="bibr19-0885066610395489">
<label>19</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ti</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Kang</surname>
<given-names>SC</given-names>
</name>
<name>
<surname>Cheong</surname>
<given-names>KF.</given-names>
</name>
</person-group> <article-title>Acute hyponatremia secondary to cerebral salt wasting syndrome in a patient with tuberculous meningitis</article-title>. <source>Anaesth Intensive Care</source>. <year>1998</year>;<volume>26</volume>(<issue>4</issue>):<fpage>420</fpage>.</citation>
</ref>
<ref id="bibr20-0885066610395489">
<label>20</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Erduran</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Mocan</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Aslan</surname>
<given-names>Y.</given-names>
</name>
</person-group> <article-title>Another cause of hyponatremia in patients with bacterial meningitis</article-title>. <source>Acta Peadiatr</source>. <year>1997</year>;<volume>349</volume>(<issue>5</issue>):<fpage>245</fpage>.</citation>
</ref>
<ref id="bibr21-0885066610395489">
<label>21</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Soualmia</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Ayadi</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Omar</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Feki</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Drissa</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Mebazaa</surname>
<given-names>A</given-names>
</name>
<etal/>
</person-group>. <article-title>Atrial natriuretic peptide and brain natriuretic peptide release in human essential hypertension</article-title>. <source>Clin Lab</source>. <year>2009</year>;<volume>55</volume>(<issue>3-4</issue>):<fpage>120</fpage>–<lpage>127</lpage>.</citation>
</ref>
<ref id="bibr22-0885066610395489">
<label>22</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zellner</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Protter</surname>
<given-names>AA</given-names>
</name>
<name>
<surname>Ko</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Pothireddy</surname>
<given-names>MR</given-names>
</name>
<name>
<surname>DeMarco</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Hutchison</surname>
<given-names>SJ</given-names>
</name>
<etal/>
</person-group>. <article-title>Coronary vasodilator effects of BNP: mechanisms of action in coronary conductance</article-title>. <source>Am J Physiol</source>. <year>1999</year>;<volume>276</volume>(<issue>3</issue>):<fpage>H1049</fpage>–<lpage>H1057</lpage>.</citation>
</ref>
<ref id="bibr23-0885066610395489">
<label>23</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>John</surname>
<given-names>K.</given-names>
</name>
</person-group> <article-title>Maesaka, Sandeep Gupta, Steven Fishbane. Cerebral salt-wasting syndrome: does it exist?</article-title> <source>Nephron</source>. <year>1999</year>;<volume>82</volume>(<issue>2</issue>):<fpage>100</fpage>–<lpage>109</lpage>.</citation>
</ref>
<ref id="bibr24-0885066610395489">
<label>24</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Verbalis</surname>
<given-names>JG.</given-names>
</name>
</person-group> <article-title>Pathogenesis of hyponatremia in an experimental model of the syndrome of inappropriate antidiuresis</article-title>. <source>Am J Phsiol</source>. <year>1994</year>;<volume>267</volume>(<issue>6</issue>):<fpage>R1617</fpage>.</citation>
</ref>
<ref id="bibr25-0885066610395489">
<label>25</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Levin</surname>
<given-names>ER</given-names>
</name>
<name>
<surname>Gardner</surname>
<given-names>DG</given-names>
</name>
<name>
<surname>Samson</surname>
<given-names>WK.</given-names>
</name>
</person-group> <article-title>Natruretic peptides</article-title>. <source>N Engl J Med</source>. <year>1998</year>;<volume>339</volume>(<issue>1</issue>):<fpage>321</fpage>.</citation>
</ref>
<ref id="bibr26-0885066610395489">
<label>26</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brimioulle</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Orellana-Jimenez</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Aminian</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Vincent</surname>
<given-names>JL.</given-names>
</name>
</person-group> <article-title>Hyponatremia in neurological patients: cerebral salt wasting versus inappropriate antidiuretic hormone secretion</article-title>. <source>Intensive Care Med</source>. <year>2008</year>;<volume>34</volume>(<issue>1</issue>):<fpage>125</fpage>–<lpage>131</lpage>.<comment>. Epub 2007 Oct</comment>
</citation>
</ref>
<ref id="bibr27-0885066610395489">
<label>27</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cole</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Gottfried</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>JK</given-names>
</name>
<name>
<surname>Couldwell</surname>
<given-names>WT.</given-names>
</name>
</person-group> <article-title>Hyponatremia in the neurosurgical patient: diagnosis and management</article-title>. <source>Neurosurg Focus</source>. <year>2004</year>;<volume>16</volume>(<issue>4</issue>):<fpage>Article 9</fpage>.</citation>
</ref>
<ref id="bibr28-0885066610395489">
<label>28</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Verbalis</surname>
<given-names>JG</given-names>
</name>
<name>
<surname>Goldsmith</surname>
<given-names>SR</given-names>
</name>
<name>
<surname>Greenberg</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Schrier</surname>
<given-names>RW</given-names>
</name>
<name>
<surname>Sterns</surname>
<given-names>RH.</given-names>
</name>
</person-group> <article-title>Hyponatremia treatment guidelines 2007: expert panel recommendations</article-title>. <source>Am J Med</source>. <year>2007</year>;<volume>120</volume>(<issue>11 suppl 1</issue>):<fpage>S1</fpage>–<lpage>S21</lpage>.</citation>
</ref>
<ref id="bibr29-0885066610395489">
<label>29</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Androgue</surname>
<given-names>HJ</given-names>
</name>
<name>
<surname>Madias</surname>
<given-names>NE.</given-names>
</name>
</person-group> <article-title>Hyponatremia</article-title>. <source>N Engl J Med</source>. <year>2000</year>;<volume>342</volume>(<issue>21</issue>):<fpage>1581</fpage>.</citation>
</ref>
<ref id="bibr30-0885066610395489">
<label>30</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kurokawa</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Uede</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Ishiguro</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>Pathogenesis of hyponatremia following subarachnoid hemorrhage due to ruptured cerebral aneurysm</article-title>. <source>Surgical Neurol</source>. <year>1996</year>;<volume>46</volume>(<issue>5</issue>):<fpage>500</fpage>–<lpage>508</lpage>.</citation>
</ref>
<ref id="bibr31-0885066610395489">
<label>31</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nakagawa</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Kurokawa</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Takayama</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Wada</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Nakase</surname>
<given-names>H.</given-names>
</name>
</person-group> <article-title>Increased urinary sodium excretion in the early phase of aneurysmal subarachnoid hemorrhage as a predictor of cerebral salt wasting syndrome</article-title>. <source>Brain Nerve</source>. <year>2009</year>;<volume>61</volume>(<issue>12</issue>):<fpage>1419</fpage>–<lpage>1423</lpage>.</citation>
</ref>
<ref id="bibr32-0885066610395489">
<label>32</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zeltser</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Rosansky</surname>
<given-names>S</given-names>
</name>
<name>
<surname>van Rensburg</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Verbalis</surname>
<given-names>JG</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>N.</given-names>
</name>
</person-group> <article-title>Assessment of the efficacy and safety of intravenous conivaptan in euvolemic and hypervolemic hyponatremia</article-title>. <source>Am J Nephrol</source>. <year>2007</year>;<volume>27</volume>(<issue>5</issue>):<fpage>337</fpage>–<lpage>457</lpage>.</citation>
</ref>
<ref id="bibr33-0885066610395489">
<label>33</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wright</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Asbury</surname>
<given-names>WH</given-names>
</name>
<name>
<surname>Gilmore</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Samuels</surname>
<given-names>OR.</given-names>
</name>
</person-group> <article-title>Conivaptin for hyponatremia in the neuro critical care unit</article-title>. <source>Neurocrit Care</source>. <year>2008</year>;<volume>10</volume>(<issue>1</issue>):<fpage>1007</fpage>.</citation>
</ref>
<ref id="bibr34-0885066610395489">
<label>34</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Olson</surname>
<given-names>BR.</given-names>
</name>
</person-group> <article-title>Vasopressin-receptor antagonists: a new class of agents for the treatment of hyponatremia</article-title>. <source>Endocr Metab Immune Disord Drug Targets</source>. <year>2006</year>;<volume>6</volume>(<issue>3</issue>):<fpage>249</fpage>–<lpage>258</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>